中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

2064 records (took 0.165 seconds)

    TREATMENT OF PROSTATE CANCER
    83.
    发明申请
    TREATMENT OF PROSTATE CANCER 有权

    公开(公告)号：US20220401443A1

    公开(公告)日：2022-12-22

    申请号：US17866203

    申请日：2022-07-15

    Applicant: Myovant Sciences GmbH ,  Takeda Pharmaceutical Company Limited

    Inventor： Vijaykumar Reddy RAJASEKHAR ,  Brendan Mark JOHNSON ,  David B. MACLEAN ,  Lynn SEELY ,  Paul N. MUDD, JR.

    IPC: A61K31/501 ,  A61P35/00 ,  A61K31/513 ,  A61K9/00 ,  A61K31/4166

    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

    METHOD FOR PRODUCING RENAL INTERSTITIAL CELL
    87.
    发明申请
    METHOD FOR PRODUCING RENAL INTERSTITIAL CELL 有权

    公开(公告)号：US20220313733A1

    公开(公告)日：2022-10-06

    申请号：US17618080

    申请日：2020-06-10

    Applicant: Kyoto University ,  Takeda Pharmaceutical Company Limited

    Inventor： Makoto IKEYA ,  Daisuke KAMIYA

    IPC: A61K35/12 ,  C12N5/0797 ,  C12N5/071

    Abstract: A method for producing renal stromal cells, comprising a step (3) of culturing renal stromal precursors in a medium comprising a platelet derived growth factor receptor agonist to obtain renal stromal cells is provided as a technique for supplying renal stromal cells. This production method can further comprise a step (2) of inducing renal stromal precursors from neural crest cells, and a step (1) of culturing pluripotent stem cells in a medium comprising a GSK3β inhibitor, a TGFβ inhibitor, and retinoic acid and/or a derivative thereof to induce neural crest cells.

    TREATMENT OF GASTROPARESIS WITH TRIAZASPIRO[4.5]DECANONE
    89.
    发明申请
    TREATMENT OF GASTROPARESIS WITH TRIAZASPIRO[4.5]DECANONE 有权

    公开(公告)号：US20220288042A1

    公开(公告)日：2022-09-15

    申请号：US17829439

    申请日：2022-06-01

    Applicant: Takeda Pharmaceutical Company Limited

    Inventor： Emil Chuang

    IPC: A61K31/438 ,  A61P1/14

    Abstract: Provided herein is a method of treating or alleviating one or more symptoms of a disorder, disease, or condition mediated by a dopamine D2 or D3 receptor with 3-((1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl)methyl)benzoic acid or a pharmaceutically acceptable salt thereof. Also provided herein is a method of increasing the scrum prolactin level with 3-((1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl)methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

    TRANSFECTION METHOD
    90.
    发明申请
    TRANSFECTION METHOD 有权

    公开(公告)号：US20220251576A1

    公开(公告)日：2022-08-11

    申请号：US17622580

    申请日：2020-06-25

    Applicant: Takeda Pharmaceutical Company Limited

    Inventor： Naoyuki MURATA ,  Sayan CHUANOI ,  Shigeo YANAI

    IPC: C12N15/64 ,  C07K14/725 ,  A61P37/00 ,  A61K9/00 ,  A61K9/51 ,  A61K9/08 ,  A61K47/26

    Abstract: A novel means for safely and efficiently introducing a target substance such as nucleic acid, protein, or the like into immune cells such as T cell and the like is provided by the present invention. Thus, a system for delivering a target substance into an immune cell, including ultrafine bubble water or ultrafine bubble aqueous solution containing ultrafine bubbles with an average diameter of not more than 200 nm and not containing phospholipid, and an ultrasound generator in combination; a method for increasing the delivery of a nucleic acid or a protein into an immune cell by using the ultrafine bubble water, etc. and ultrasound; and the like are provided.

Patent Agency Ranking